Terry Chrisomalis @BioAnalysisCent

Founder of "Biotech Analysis Central" marketplace at Seeking Alpha, Biotech author at Seeking Alpha Journalist of Biotech, Follow me on Stocktwits BiopharmaPro seekingalpha.com/author/terry-c… Joined May 2018

Tweets

505
Followers

719
Following

2K
Likes

95

Patent Pundit @PunditPatent

5 years ago

$ABUS - The Patent Office issued ABUS it's newest patent this morning. IMO, the new patent covers both the $MRNA and $PFE / $BNTX vaccines. It has an effective filing date (for prior art) dating back to 2009.

Patent Pundit @PunditPatent

5 years ago

In addition to covering the $MRNA Covid Vaccine, it looks like the new patent application that $ABUS got allowed on August 30, 2021 (app. no. 17/227802) also covers the Pfizer-BioNTech Covid Vaccine.

1 5 33 0 5

5 25 92 0 7

View Details

Terry Chrisomalis @BioAnalysisCent

5 years ago

$CLDX "Celldex's Latest Data For Chronic Inducible Urticaria Drug Is Only The Beginning" seekingalpha.com/article/443892…

0 0 0 0 1

View Details

Terry Chrisomalis @BioAnalysisCent

5 years ago

$ABUS "Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment" seekingalpha.com/article/443707…

1 0 0 0 1

View Details

Terry Chrisomalis @BioAnalysisCent

5 years ago

$ABUS Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection biospace.com/article/releas…

0 0 1 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

5 years ago

$ABUS "Arbutus Announces New Data On Ab-729 And Ab-836 Programs With Presentation Of Five Abstracts At The Easl International Liver Congress™ 2021 - All Selected For Best Of Ilc™" globenewswire.com/news-release/2…

0 0 1 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

5 years ago

$EPZM "Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge" seekingalpha.com/article/443608…

0 0 0 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

5 years ago

$ABUS "Biotech Analysis Central Preview Series: Arbutus Biopharma" seekingalpha.com/instablog/1058…

1 0 2 0 1

View Details

Terry Chrisomalis @BioAnalysisCent

5 years ago

seekingalpha.com/instablog/1058…

0 0 0 0 0

View Details

Dirk Haussecker @RNAiAnalyst

6 years ago

RUN!!!! Had a feeling this would be a $arct-type disaster.

zach @zbiotech

6 years ago

no bueno $VXRT

3 5 16 0 0

4 4 13 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

$ABUS #HBV $ARWR $VIR $DRNA investor.arbutusbio.com/news-releases/…

Dirk Haussecker @RNAiAnalyst

6 years ago

$ABUS Excellent: giving #HBV RNAi compound AB-729 every 8 weeks same efficacy as every 4 weeks. Benefit not just patient convenience, but better liver safety. -->Indeed, liver safety profile in 8 week cohort better than in 4 week. $ARWR $VIR $DRNA

3 6 30 0 0

0 0 0 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

@RNAiAnalyst $ABUS Recent HBV data, but more importantly another catalyst. They still releasing AB-729 60 mg multi-dose every 8-weeks dose. If they can prove up to every 8 weeks or every 12-weeks that would be huge for Hep B treatment. This is coming any day now Q4 2020.

0 0 8 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

$ABUS $DRNA $VIR $ALNY $ARWR $JNJ

Dirk Haussecker @RNAiAnalyst

6 years ago

#HBV RNAi...AASLD updates provided 1st snapshots of single shot knockdown for $ABUS competition. Here, $DRNA's/Roche's RG6346 comes up short in kd duration: $VIR $ALNY $ARWR $JNJ

3 5 20 0 2

1 2 3 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

@biot_notes @MedResCol Read the data The final 16 weeks multi-dose did not reach plateau. 3 patients still getting -1.73 and still declining. That is only 16 weeks. You can't compare the other companies which have observed 24 weeks or 48 weeks. That fast of a decline in HBV in that short of a time good

0 0 1 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

$ABUS Impressed that the 60 mg AB-729 multi-dose (once every 4 weeks) hasn't reached a plateau past 16 weeks. Mean reduction of -1.44 log IU/ML at week 16 in Hepatitis B patients, no plateau yet past week 16.

Dirk Haussecker @RNAiAnalyst

6 years ago

#HBV RNAi...AASLD updates provided 1st snapshots of single shot knockdown for $ABUS competition. Here, $DRNA's/Roche's RG6346 comes up short in kd duration: $VIR $ALNY $ARWR $JNJ

3 5 20 0 2

0 0 3 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

$ABUS Going to present at AASLD On Sunday November 15, 2020 , with press release afterwards on results. Monday November 16th conference call to discuss data. First look at 60 mg AB-729 multi-dose cohort, plus long-term single dose cohorts of 60 mg and 90 mg of AB-729 for Hep B

0 2 4 0 0

View Details

Dirk Haussecker @RNAiAnalyst

6 years ago

$ABUS tempted to buy here on weakness ahead of HBV RNAi multi-dose presentation at AASLD; but then again: if data good, they'll sell more shares.

5 1 12 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

$VRTX $MRNA Biotech Analysis Central "Vertex Looks To Target 10% Of Cystic Fibrosis Population Not Yet Achieved By Its Current CFTR Modulators" seekingalpha.com/article/437861…

0 0 0 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

$CRDF Biotech Analysis Central "Cardiff Oncology's Onvansertib Could Possibly End Up Being A Solid Cancer Drug" seekingalpha.com/article/437859…

0 0 0 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

$MRTX Biotech Analysis Central "Mirati Will Continue To Shine As It Keeps Delivering Promising Results" seekingalpha.com/article/437856…

0 0 0 0 0

View Details

Terry Chrisomalis @BioAnalysisCent

6 years ago

$ALX $MRK $GILD $TRIL Biotech Analysis Central "ALX Oncology Is A Promising CD47 Targeting Biotech With Massive Potential" seekingalpha.com/article/437603…